1
|
Cunha-Garcia D, Monteiro-Fernandes D, Correia JS, Neves-Carvalho A, Vilaça-Ferreira AC, Guerra-Gomes S, Viana JF, Oliveira JF, Teixeira-Castro A, Maciel P, Duarte-Silva S. Genetic Ablation of Inositol 1,4,5-Trisphosphate Receptor Type 2 (IP 3R2) Fails to Modify Disease Progression in a Mouse Model of Spinocerebellar Ataxia Type 3. Int J Mol Sci 2023; 24:10606. [PMID: 37445783 PMCID: PMC10341520 DOI: 10.3390/ijms241310606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 06/07/2023] [Accepted: 06/16/2023] [Indexed: 07/15/2023] Open
Abstract
Spinocerebellar ataxia type 3 (SCA3) is a rare neurodegenerative disease caused by an abnormal polyglutamine expansion within the ataxin-3 protein (ATXN3). This leads to neurodegeneration of specific brain and spinal cord regions, resulting in a progressive loss of motor function. Despite neuronal death, non-neuronal cells, including astrocytes, are also involved in SCA3 pathogenesis. Astrogliosis is a common pathological feature in SCA3 patients and animal models of the disease. However, the contribution of astrocytes to SCA3 is not clearly defined. Inositol 1,4,5-trisphosphate receptor type 2 (IP3R2) is the predominant IP3R in mediating astrocyte somatic calcium signals, and genetically ablation of IP3R2 has been widely used to study astrocyte function. Here, we aimed to investigate the relevance of IP3R2 in the onset and progression of SCA3. For this, we tested whether IP3R2 depletion and the consecutive suppression of global astrocytic calcium signalling would lead to marked changes in the behavioral phenotype of a SCA3 mouse model, the CMVMJD135 transgenic line. This was achieved by crossing IP3R2 null mice with the CMVMJD135 mouse model and performing a longitudinal behavioral characterization of these mice using well-established motor-related function tests. Our results demonstrate that IP3R2 deletion in astrocytes does not modify SCA3 progression.
Collapse
Affiliation(s)
- Daniela Cunha-Garcia
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Daniela Monteiro-Fernandes
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Joana Sofia Correia
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Andreia Neves-Carvalho
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Ana Catarina Vilaça-Ferreira
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Sónia Guerra-Gomes
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - João Filipe Viana
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - João Filipe Oliveira
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
- IPCA-EST-2Ai, Polytechnic Institute of Cávado and Ave, Applied Artificial Intelligence Laboratory, Campus of IPCA, 4750-810 Barcelos, Portugal
| | - Andreia Teixeira-Castro
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Patrícia Maciel
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| | - Sara Duarte-Silva
- Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal; (D.C.-G.); (D.M.-F.); (J.S.C.); (A.N.-C.); (A.C.V.-F.); (S.G.-G.); (J.F.V.); (J.F.O.); (A.T.-C.)
- ICVS/3B’s—PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal
| |
Collapse
|
2
|
Kapadia K, Trojniak AE, Guzmán Rodríguez KB, Klus NJ, Huntley C, McDonald P, Roy A, Frankowski KJ, Aubé J, Muma NA. Small-Molecule Disruptors of Mutant Huntingtin-Calmodulin Protein-Protein Interaction Attenuate Deleterious Effects of Mutant Huntingtin. ACS Chem Neurosci 2022; 13:2315-2337. [PMID: 35833925 PMCID: PMC11005818 DOI: 10.1021/acschemneuro.2c00305] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Abstract
Huntington's disease is a progressive and lethal neurodegenerative disease caused by an increased CAG repeat mutation in exon 1 of the huntingtin gene (mutant huntingtin). Current drug treatments provide only limited symptomatic relief without impacting disease progression. Previous studies in our lab and others identified the abnormal binding of mutant huntingtin protein with calmodulin, a key regulator of calcium signaling. Disrupting the abnormal binding of mutant huntingtin to calmodulin reduces perturbations caused by mutant huntingtin in cell and mouse models of Huntington's disease and importantly normalizes receptor-stimulated calcium release. Using a series of high-throughput in vitro and cell-based screening assays, we identified numerous small-molecule hits that disrupt the binding of mutant huntingtin to calmodulin and demonstrate protective effects. Iterative optimization of one hit resulted in nontoxic, selective compounds that are protective against mutant huntingtin cytotoxicity and normalized receptor-stimulated intracellular calcium release in PC12 cell models of Huntington's disease. Importantly, the compounds do not work by reducing the levels of mutant huntingtin, allowing this strategy to complement future molecular approaches to reduce mutant huntingtin expression. Our novel scaffold will serve as a prototype for further drug development in Huntington's disease. These studies indicate that the development of small-molecule compounds that disrupt the binding of mutant huntingtin to calmodulin is a promising approach for the advancement of therapeutics to treat Huntington's disease.
Collapse
Affiliation(s)
- Khushboo Kapadia
- Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| | - Ashley E Trojniak
- Division of Chemical Biology and Medicinal Chemistry, and the Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
| | - Kenneth B Guzmán Rodríguez
- Division of Chemical Biology and Medicinal Chemistry, and the Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
| | - Nicholas J Klus
- Division of Chemical Biology and Medicinal Chemistry, and the Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
| | - Coral Huntley
- University of Kansas High-Throughput Screening Laboratory, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Peter McDonald
- University of Kansas High-Throughput Screening Laboratory, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Anuradha Roy
- University of Kansas High-Throughput Screening Laboratory, University of Kansas, 2034 Becker Drive, Lawrence, Kansas 66047, United States
| | - Kevin J Frankowski
- Division of Chemical Biology and Medicinal Chemistry, and the Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
| | - Jeffrey Aubé
- Division of Chemical Biology and Medicinal Chemistry, and the Center for Integrative Chemical Biology and Drug Discovery, University of North Carolina, Eshelman School of Pharmacy, 125 Mason Farm Road, Chapel Hill, North Carolina 27599, United States
| | - Nancy A Muma
- Department of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, United States
| |
Collapse
|
3
|
Kraskovskaya NA, Bezprozvanny IB. Normalization of Calcium Balance in Striatal Neurons in Huntington's Disease: Sigma 1 Receptor as a Potential Target for Therapy. BIOCHEMISTRY. BIOKHIMIIA 2021; 86:471-479. [PMID: 33941067 DOI: 10.1134/s0006297921040076] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/16/2020] [Revised: 12/24/2020] [Accepted: 12/24/2020] [Indexed: 11/23/2022]
Abstract
Huntington's disease (HD) is a neurodegenerative, dominantly inherited genetic disease caused by expansion of the polyglutamine tract in the huntingtin gene. At the cellular level, HD is characterized by the accumulation of mutant huntingtin protein in brain cells, resulting in the development of the HD phenotype, which includes mental disorders, decreased cognitive abilities, and progressive motor impairments in the form of chorea. Despite numerous studies, no unambigous connection between the accumulation of mutant protein and selective death of striatal neurons has yet been established. Recent studies have shown impairments in the calcium homeostasis in striatal neurons in HD. These cells are extremely sensitive to changes in the cytoplasmic concentration of calcium and its excessive increase leads to their death. One of the possible ways to normalize the balance of calcium in striatal neurons is through the sigma 1 receptor (S1R), which act as a calcium sensor that also exhibits modulating chaperone activity upon the cell stress observed during the development of many neurodegenerative diseases. The fact that S1R is a ligand-operated protein makes it a new promising molecular target for the development of drug therapy of HD based on the agonists of this receptor.
Collapse
Affiliation(s)
- Nina A Kraskovskaya
- Laboratory of Molecular Neurodegeneration, Peter the Great Saint-Petersburg Polytechnic University, Saint-Petersburg, 195251, Russia.
| | - Ilya B Bezprozvanny
- Laboratory of Molecular Neurodegeneration, Peter the Great Saint-Petersburg Polytechnic University, Saint-Petersburg, 195251, Russia.
- Department of Physiology, UT Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
| |
Collapse
|
4
|
Morrow CS, Moore DL. Vimentin's side gig: Regulating cellular proteostasis in mammalian systems. Cytoskeleton (Hoboken) 2020; 77:515-523. [PMID: 33190414 DOI: 10.1002/cm.21645] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2020] [Revised: 11/05/2020] [Accepted: 11/09/2020] [Indexed: 02/06/2023]
Abstract
Intermediate filaments (IFs) perform a diverse set of well-known functions including providing structural support for the cell and resistance to mechanical stress, yet recent evidence has revealed unexpected roles for IFs as stress response proteins. Previously, it was shown that the type III IF protein vimentin forms cage-like structures around centrosome-associated proteins destined for degradation, structures referred to as aggresomes, suggesting a role for vimentin in protein turnover. However, vimentin's function at the aggresome has remained largely understudied. In a recent report, vimentin was shown to be dispensable for aggresome formation, but played a critical role in protein turnover at the aggresome through localizing proteostasis-related machineries, such as proteasomes, to the aggresome. Here, we review evidence for vimentin's function in proteostasis and highlight the organismal implications of these findings.
Collapse
Affiliation(s)
- Christopher S Morrow
- Department of Neuroscience, University of Wisconsin-Madison, Madison, Wisconsin, USA
| | - Darcie L Moore
- Department of Neuroscience, University of Wisconsin-Madison, Madison, Wisconsin, USA
| |
Collapse
|
5
|
Butler MR, Ma H, Yang F, Belcher J, Le YZ, Mikoshiba K, Biel M, Michalakis S, Iuso A, Križaj D, Ding XQ. Endoplasmic reticulum (ER) Ca 2+-channel activity contributes to ER stress and cone death in cyclic nucleotide-gated channel deficiency. J Biol Chem 2017; 292:11189-11205. [PMID: 28495882 DOI: 10.1074/jbc.m117.782326] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2017] [Revised: 05/01/2017] [Indexed: 02/05/2023] Open
Abstract
Endoplasmic reticulum (ER) stress and mislocalization of improperly folded proteins have been shown to contribute to photoreceptor death in models of inherited retinal degenerative diseases. In particular, mice with cone cyclic nucleotide-gated (CNG) channel deficiency, a model for achromatopsia, display both early-onset ER stress and opsin mistrafficking. By 2 weeks of age, these mice show elevated signaling from all three arms of the ER-stress pathway, and by 1 month, cone opsin is improperly distributed away from its normal outer segment location to other retinal layers. This work investigated the role of Ca2+-release channels in ER stress, protein mislocalization, and cone death in a mouse model of CNG-channel deficiency. We examined whether preservation of luminal Ca2+ stores through pharmacological and genetic suppression of ER Ca2+ efflux protects cones by attenuating ER stress. We demonstrated that the inhibition of ER Ca2+-efflux channels reduced all three arms of ER-stress signaling while improving opsin trafficking to cone outer segments and decreasing cone death by 20-35%. Cone-specific gene deletion of the inositol-1,4,5-trisphosphate receptor type I (IP3R1) also significantly increased cone density in the CNG-channel-deficient mice, suggesting that IP3R1 signaling contributes to Ca2+ homeostasis and cone survival. Consistent with the important contribution of organellar Ca2+ signaling in this achromatopsia mouse model, significant differences in dynamic intraorganellar Ca2+ levels were detected in CNG-channel-deficient cones. These results thus identify a novel molecular link between Ca2+ homeostasis and cone degeneration, thereby revealing novel therapeutic targets to preserve cones in inherited retinal degenerative diseases.
Collapse
Affiliation(s)
| | | | - Fan Yang
- From the Departments of Cell Biology
| | | | - Yun-Zheng Le
- From the Departments of Cell Biology.,Internal Medicine, and.,Ophthalmology and.,the Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104
| | - Katsuhiko Mikoshiba
- the Laboratory for Developmental Neurobiology, RIKEN Brain Science Institute, Hirosawa Wako-shi, Saitama 351-0198, Japan
| | - Martin Biel
- the Center for Integrated Protein Science Munich (CIPSM) and Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany, and
| | - Stylianos Michalakis
- the Center for Integrated Protein Science Munich (CIPSM) and Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, 81377 Munich, Germany, and
| | - Anthony Iuso
- the John A. Moran Eye Center, University of Utah, Salt Lake City, Utah 84132
| | - David Križaj
- the John A. Moran Eye Center, University of Utah, Salt Lake City, Utah 84132
| | | |
Collapse
|
6
|
Berridge MJ. The Inositol Trisphosphate/Calcium Signaling Pathway in Health and Disease. Physiol Rev 2016; 96:1261-96. [DOI: 10.1152/physrev.00006.2016] [Citation(s) in RCA: 377] [Impact Index Per Article: 47.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Many cellular functions are regulated by calcium (Ca2+) signals that are generated by different signaling pathways. One of these is the inositol 1,4,5-trisphosphate/calcium (InsP3/Ca2+) signaling pathway that operates through either primary or modulatory mechanisms. In its primary role, it generates the Ca2+ that acts directly to control processes such as metabolism, secretion, fertilization, proliferation, and smooth muscle contraction. Its modulatory role occurs in excitable cells where it modulates the primary Ca2+ signal generated by the entry of Ca2+ through voltage-operated channels that releases Ca2+ from ryanodine receptors (RYRs) on the internal stores. In carrying out this modulatory role, the InsP3/Ca2+ signaling pathway induces subtle changes in the generation and function of the voltage-dependent primary Ca2+ signal. Changes in the nature of both the primary and modulatory roles of InsP3/Ca2+ signaling are a contributory factor responsible for the onset of a large number human diseases.
Collapse
Affiliation(s)
- Michael J. Berridge
- Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge, CB22 3AT, United Kingdom
| |
Collapse
|
7
|
Hensel N, Rademacher S, Claus P. Chatting with the neighbors: crosstalk between Rho-kinase (ROCK) and other signaling pathways for treatment of neurological disorders. Front Neurosci 2015; 9:198. [PMID: 26082680 PMCID: PMC4451340 DOI: 10.3389/fnins.2015.00198] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2015] [Accepted: 05/18/2015] [Indexed: 12/11/2022] Open
Abstract
ROCK inhibition has been largely applied as a strategy to treat neurodegenerative diseases (NDDs) and promising results have been obtained in the recent years. However, the underlying molecular and cellular mechanisms are not fully understood and different models have been proposed for neurodegenerative disorders. Here, we aim to review the current knowledge obtained for NDDs identifying common mechanisms as well as disease-specific models. In addition to the role of ROCK in different cell types such as neurons and microglia, we focus on the molecular signaling-pathways which mediate the beneficial effects of ROCK. Besides canonical ROCK signaling, modulation of neighboring pathways by non-canonical ROCK-crosstalk is a recurrent pattern in many NDD-model systems and has been suggested to mediate beneficial effects of ROCK-inhibition.
Collapse
Affiliation(s)
- Niko Hensel
- Hannover Medical School, Institute of Neuroanatomy Hannover, Germany ; Niedersachsen Research Network on Neuroinfectiology Hannover, Germany
| | - Sebastian Rademacher
- Hannover Medical School, Institute of Neuroanatomy Hannover, Germany ; Center for Systems Neuroscience Hannover, Germany
| | - Peter Claus
- Hannover Medical School, Institute of Neuroanatomy Hannover, Germany ; Niedersachsen Research Network on Neuroinfectiology Hannover, Germany ; Center for Systems Neuroscience Hannover, Germany
| |
Collapse
|
8
|
2-Aminoethyl diphenylborinate (2-APB) analogues: regulation of Ca2+ signaling. Biochem Biophys Res Commun 2013; 441:286-90. [PMID: 24036266 DOI: 10.1016/j.bbrc.2013.08.102] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2013] [Accepted: 08/30/2013] [Indexed: 11/24/2022]
Abstract
In order to obtain compounds with modified 2-APB activities, we synthesized number of 2-APB analogues and analyzed their inhibitory activities for SOCE. The IC50 of 2-APB for SOCE inhibition is 3 μM while IC50 of some of our 2-APB analogues range 0.1-10 μM. The adducts of amino acids with diphenyl borinic acid have strong inhibitory activities. By using these compounds, we will be able to regulate intracellular Ca(2+) concentration and consequent cellular processes more efficiently than with 2-APB.
Collapse
|
9
|
Margulis BA, Vigont V, Lazarev VF, Kaznacheyeva EV, Guzhova IV. Pharmacological protein targets in polyglutamine diseases: mutant polypeptides and their interactors. FEBS Lett 2013; 587:1997-2007. [PMID: 23684638 DOI: 10.1016/j.febslet.2013.05.022] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Accepted: 05/06/2013] [Indexed: 12/18/2022]
Abstract
Polyglutamine diseases are a group of pathologies affecting different parts of the brain and causing dysfunction and atrophy of certain neural cell populations. These diseases stem from mutations in various cellular genes that result in the synthesis of proteins with extended polyglutamine tracts. In particular, this concerns huntingtin, ataxins, and androgen receptor. These mutant proteins can form oligomers, aggregates, and, finally, aggresomes with distinct functions and different degrees of cytotoxicity. In this review, we analyze the effects of different forms of polyQ proteins on other proteins and their functions, which are considered as targets for therapeutic intervention.
Collapse
Affiliation(s)
- Boris A Margulis
- Institute of Cytology of Russian Academy of Sciences, Tikhoretsky pr., 4, St. Petersburg 194064, Russia
| | | | | | | | | |
Collapse
|
10
|
Giacomello M, Oliveros JC, Naranjo JR, Carafoli E. Neuronal Ca(2+) dyshomeostasis in Huntington disease. Prion 2013; 7:76-84. [PMID: 23324594 DOI: 10.4161/pri.23581] [Citation(s) in RCA: 40] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
The expansion of the N-terminal poly-glutamine tract of the huntingtin (Htt) protein is responsible for Huntington disease (HD). A large number of studies have explored the neuronal phenotype of HD, but the molecular aethiology of the disease is still very poorly understood. This has hampered the development of an appropriate therapeutical strategy to at least alleviate its symptoms. In this short review, we have focused our attention on the alteration of a specific cellular mechanism common to all HD models, either genetic or induced by treatment with 3-NPA, i.e. the cellular dyshomeostasis of Ca(2+). We have highlighted the direct and indirect (i.e. transcriptionally mediated) effects of mutated Htt on the maintenance of the intracellular Ca(2+) balance, the correct modulation of which is fundamental to cell survival and the disturbance of which plays a key role in the death of the cell.
Collapse
|
11
|
Suzuki M, Nagai Y, Wada K, Koike T. Calcium leak through ryanodine receptor is involved in neuronal death induced by mutant huntingtin. Biochem Biophys Res Commun 2012; 429:18-23. [DOI: 10.1016/j.bbrc.2012.10.107] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2012] [Accepted: 10/24/2012] [Indexed: 01/24/2023]
|
12
|
Bauer PO, Hudec R, Goswami A, Kurosawa M, Matsumoto G, Mikoshiba K, Nukina N. ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. Mol Neurodegener 2012; 7:43. [PMID: 22929228 PMCID: PMC3502191 DOI: 10.1186/1750-1326-7-43] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2012] [Accepted: 08/06/2012] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Huntington's Disease (HD) is a fatal hereditary neurodegenerative disease caused by the accumulation of mutant huntingtin protein (Htt) containing an expanded polyglutamine (polyQ) tract. Activation of the channel responsible for the inositol-induced Ca²⁺ release from ensoplasmic reticulum (ER), was found to contribute substantially to neurodegeneration in HD. Importantly, chemical and genetic inhibition of inositol 1,4,5-trisphosphate (IP3) receptor type 1 (IP3R1) has been shown to reduce mutant Htt aggregation. RESULTS In this study, we propose a novel regulatory mechanism of IP3R1 activity by type III intermediate filament vimentin which sequesters the negative regulator of IP3R1, IRBIT, into perinuclear inclusions, and reduces its interaction with IP3R1 resulting in promotion of mutant Htt aggregation. Proteasome inhibitor MG132, which causes polyQ proteins accumulation and aggregation, enhanced the sequestration of IRBIT. Furthermore we found that IRBIT sequestration can be prevented by a rho kinase inhibitor, Y-27632. CONCLUSIONS Our results suggest that vimentin represents a novel and additional target for the therapy of polyQ diseases.
Collapse
Affiliation(s)
- Peter O Bauer
- Laboratory for Structural Neuropathology, Brain Science Institute, RIKEN, 2-1 Hirosawa, Wako-shi, Saitama 351-0198, Japan
| | | | | | | | | | | | | |
Collapse
|